Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cutaneous Radiation Injury Treatment Market size is likely to expand at more than 4.5% CAGR during the forecast period i.e., between 2025-2037.
The market’s growth can be attributed to growing prevalence of cancer and rising adoption of radiation therapy for the treatment of cancer patients. For instance, as per the statistics by GLOBOCAN, the (5-year) prevalence of cancer was 50,550,287 globally in 2020. Along with this, rising availability of topical creams, increasing healthcare awareness among population, growing geriatric population, and emergence of various online pharmacies is expected to drive the market growth in the upcoming years.
Cutaneous Radiation Injury Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing adoption of radiation therapies for the treatment of cancer patients
- Growing awareness regarding radiation-induced skin damages
Challenges
- Lack of proper health facilities in developing countries
Cutaneous Radiation Injury Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.5% |
|
|
|
|
|
|
|
Regional Scope |
|
Cutaneous Radiation Injury Treatment Segmentation
Based on product, the global cutaneous radiation injury treatment market is segmented into topical, dressings, and oral drugs. The topical segment accounted for the largest market size in value in 2021 on account of increasing product launch by various manufacturers across the globe coupled with rising risks of developing radiation burns. On the other hand, the dressing segment is anticipated to grow with the highest CAGR during the forecast period.
On the basis of exposure, the market is segmented into contamination and irradiation, out of which the irradiation segment captured a significant share of the market in 2021. Further, the segment is projected to grow during the forecast period on account of factors, such as increasing number of patients diagnosed with cancer and rising use of radiation therapy for cancer treatment.
Based on stage, the market is classified into prodromal stage, latent stage, manifest illness stage, third wave of erythema, and late effects. Among them, the third wave of erythema segment is anticipated to grab a significant share by 2031 owing to discomforts experienced by the exposed persons during this stage and increasing number of people affected by high grade radiations.
Based on distribution channel, the global cutaneous radiation injury treatment market is segmented into online pharmacy, and offline pharmacy, of which the offline pharmacy segment held the highest share in 2021 on account of growing retail pharmacy and increasing availability of products as offline pharmacy is easily accessible to people.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Exposure |
|
|
By Stage |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCutaneous Radiation Injury Treatment Industry - Regional Synopsis
Asia Pacific industry is likely to account for largest revenue share by 2037, owing to increasing awareness among the population about available treatment for radiation injuries, rising healthcare awareness, and growing cancer incidence., owing to increasing awareness among the population about available treatment for radiation injuries, rising healthcare awareness, and growing cancer incidence. Furthermore, in 2021, the market in North America occupied the largest revenue share, owing to the high prevalence of cancer and presence of leading healthcare service providers in the region. Along with this, North America has an increasingly aging population, which is expected to contribute to the market growth in the upcoming years. As per the Data released by the World Bank, in 2020, the total geriatric population in the USA was 55,131,698.
Companies Dominating the Cutaneous Radiation Injury Treatment Landscape
- 3M Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Stratpharma AG
- Intermed S.A.
- Helsinn Healthcare SA
- Mölnlycke Health Care AB
- BMG PHARMA S.p.A.
- Convatec Inc.
- AceTech
- Meabco A/S
- KeraNetics, Inc.
In the News
- March 2022: KeraNetics Inc. was awarded a contract of USD 3.5 million from the Biomedical Advanced Research and Development Authority (BARDA), to conduct the required pivotal studies to expand the product indications in Cutaneous Radiation Injury or CRI management.
- March 2022: BioCurity Pharmaceuticals, Inc., a biopharmaceutical company announced the launch of supportive cancer drug designed for the prevention of radiation therapy side effects.
Author Credits: Radhika Pawar
- Report ID: 4154
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
